Race Oncology Ltd has released a press release.
Pause in Trading
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Executes Contracts to Commence Breast Cancer Trial
- New Collaboration to Understand Zantrene Cardioprotection
- Race Receives Cardioprotection Ethics Trial Approval
- Race supports Study of Extramedullary AML
- Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
Later from Racura Oncology
- Race Leadership Changes
- Race Receives $1.48m R&D Tax Refund for Financial Year 2022
- Race releases cardioprotection market potential data
- Race releases complete cardio-protection data & video
- Letter to Shareholders
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology